These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 8092350)

  • 21. Buspirone augmentation of fluoxetine in patients with obsessive compulsive disorder.
    Jenike MA; Baer L; Buttolph L
    J Clin Psychiatry; 1991 Jan; 52(1):13-4. PubMed ID: 1988411
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder.
    McDougle CJ; Goodman WK; Leckman JF; Holzer JC; Barr LC; McCance-Katz E; Heninger GR; Price LH
    Am J Psychiatry; 1993 Apr; 150(4):647-9. PubMed ID: 8465885
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An open trial of buspirone in obsessive-compulsive disorder.
    Jenike MA; Baer L
    Am J Psychiatry; 1988 Oct; 145(10):1285-6. PubMed ID: 3048120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder.
    Pato MT; Zohar-Kadouch R; Zohar J; Murphy DL
    Am J Psychiatry; 1988 Dec; 145(12):1521-5. PubMed ID: 3057923
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential cerebral metabolic changes with paroxetine treatment of obsessive-compulsive disorder vs major depression.
    Saxena S; Brody AL; Ho ML; Alborzian S; Maidment KM; Zohrabi N; Ho MK; Huang SC; Wu HM; Baxter LR
    Arch Gen Psychiatry; 2002 Mar; 59(3):250-61. PubMed ID: 11879163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of nitric oxide in obsessive-compulsive behavior and its involvement in the anti-compulsive effect of paroxetine in mice.
    Umathe SN; Bhutada PS; Jain NS; Mundhada YR; Borkar SS; Dhumal B
    Nitric Oxide; 2009 Sep; 21(2):140-7. PubMed ID: 19584001
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of glutamatergic dysfunction in treatment-resistant obsessive-compulsive disorder: treatment of an adolescent case with N-acetylcysteine augmentation.
    Yazici KU; Percinel I
    J Child Adolesc Psychopharmacol; 2014 Nov; 24(9):525-7. PubMed ID: 25264963
    [No Abstract]   [Full Text] [Related]  

  • 28. Paroxetine-induced enuresis.
    Toros F; Erdoğan K
    Eur Psychiatry; 2003 Feb; 18(1):43-4. PubMed ID: 12648899
    [No Abstract]   [Full Text] [Related]  

  • 29. Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder?
    Koran LM; Cain JW; Dominguez RA; Rush AJ; Thiemann S
    Am J Psychiatry; 1996 Nov; 153(11):1450-4. PubMed ID: 8890679
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Obsessive-compulsive disorder: a double-blind, placebo-controlled trial of clomipramine in 27 patients.
    Jenike MA; Baer L; Summergrad P; Weilburg JB; Holland A; Seymour R
    Am J Psychiatry; 1989 Oct; 146(10):1328-30. PubMed ID: 2675643
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Open-label study of duloxetine for the treatment of obsessive-compulsive disorder.
    Dougherty DD; Corse AK; Chou T; Duffy A; Arulpragasam AR; Deckersbach T; Jenike MA; Keuthen NJ
    Int J Neuropsychopharmacol; 2015; 18(2):. PubMed ID: 25637377
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aripiprazole treatment in an adolescent patient with chronic motor tic disorder and treatment-resistant obsessive-compulsive disorder.
    Lai CH
    Int J Neuropsychopharmacol; 2009 Oct; 12(9):1291-3. PubMed ID: 19706223
    [No Abstract]   [Full Text] [Related]  

  • 33. Lithium and tryptophan augmentation in clomipramine-resistant obsessive-compulsive disorder.
    Rasmussen SA
    Am J Psychiatry; 1984 Oct; 141(10):1283-5. PubMed ID: 6435460
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful treatment of comorbid obsessive-compulsive disorder with aripiprazole in three patients with bipolar disorder.
    Uguz F
    Gen Hosp Psychiatry; 2010; 32(5):556-8. PubMed ID: 20851277
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-androgenic treatment of obsessive-compulsive disorder: an open-label clinical trial of the long-acting gonadotropin-releasing hormone analogue triptorelin.
    Eriksson T
    Int Clin Psychopharmacol; 2007 Jan; 22(1):57-61. PubMed ID: 17159461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cutaneous vasculitis induced by paroxetine.
    Margolese HC; Chouinard G; Beauclair L; Rubino M
    Am J Psychiatry; 2001 Mar; 158(3):497. PubMed ID: 11230000
    [No Abstract]   [Full Text] [Related]  

  • 37. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison.
    Freeman CP; Trimble MR; Deakin JF; Stokes TM; Ashford JJ
    J Clin Psychiatry; 1994 Jul; 55(7):301-5. PubMed ID: 8071291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of clozapine-induced obsessive-compulsive symptoms in a man with schizophrenia.
    Zink M; Knopf U; Kuwilsky A
    Aust N Z J Psychiatry; 2007 Mar; 41(3):293-4. PubMed ID: 17464712
    [No Abstract]   [Full Text] [Related]  

  • 39. Paroxetine-induced psychotic mania.
    Christensen RC
    Am J Psychiatry; 1995 Sep; 152(9):1399-400. PubMed ID: 7653703
    [No Abstract]   [Full Text] [Related]  

  • 40. [Utilization of thought stopping in the treatment of obsessive- compulsive disorder in a 9 year old girl].
    Frare P; Lebel A
    Can J Psychiatry; 1996 Aug; 41(6):367-70. PubMed ID: 8983816
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.